Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Souhir, Neffati"'
Autor:
William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. Methods Main inclusion criteria for screening were as fo
Externí odkaz:
https://doaj.org/article/eb8133670a8c471b9655035877df2e22
Autor:
Souhir Neffati, Jean-Yves Pierga, M. Ezzalfani, Véronique Mosseri, Frédérique Berger, Fatima Laki, Youlia M. Kirova, Alain Fourquet, Francesco Ricci, Marie Paule Sablin, Cyrine Ezzili, L. Bazire, Delphine Loirat, A. Chilles, Laurence Raizoville, Manuel Rodrigues, Claire Bertrand, Anne Vincent Salomon
Publikováno v:
Cancer Research. 80:OT2-03
Background Preclinical studies have shown that breast cancer (BC) cell lines with a triple-negative phenotype are more sensitive to PARP1 inhibitors compared with non-TNBC cells. All these lines of evidence provide a strong rationale for developing a
Autor:
Jean-Yves Pierga, V. Servent, Véronique D'Hondt, Hugues Bourgeois, Véronique Diéras, William Jacot, Laurence Venat-Bouvet, Marie-Paule Sablin, Elisabeth Luporsi, Séverine Guiu, François-Clément Bidard, Frédérique Berger, Etienne Brain, Marc A. Bollet, Marc Espié, Alain Lortholary, Souhir Neffati, Coraline Dubot, Paul Cottu
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
BackgroundIn this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.MethodsMain inclusion criteria for screening were as follows: women
Autor:
Francesco Ricci, Souhir Neffati, Cyrine Ezzili, L. Bazire, Laurence Raizonville, Fatima Laki, Pierre Loap, Alain Fourquet, K.I. Cao, Véronique Mosseri, J-Y Pierga, Y.M. Kirova, Anne Vincent-Salomon, Delphine Loirat, M. Ezzalfani, Frédérique Berger, Manuel Rodrigues
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S8
Purpose/Objective(s) Preclinical studies have found that triple-negative breast cancer (TNBC) cells were sensitive to PARP1 inhibitors. The phase I dose-escalation RADIOPARP trial evaluated in TNBC patients the combination of breast radiotherapy and
Autor:
Jacot, William, Cottu, Paul, Berger, Frederique, Dubot, Coraline, Venat-Bouvet, Laurence, Lortholary, Alain, Bourgeois, Hugues, Bollet, Marc, Servent, Veronique, Luporsi, Elisabeth, Espié, Marc, Guiu, Severine, D’Hondt, Veronique, Dieras, Veronique, Marie-Paule Sablin, Brain, Etienne, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Additional file 2. Table S1. Univariate and multivariate analyses for PFS and OS (screened population). For multivariate analyses, only significant results are shown. MBC: metastatic breast cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ade0324f1681e6936358bf3c8e89c94
Autor:
Alain Fourquet, Delphine Loirat, Cyrine Ezzili, Frédérique Berger, K.I. Cao, L. Bazire, Youlia M. Kirova, Francesco Ricci, Manuel Rodrigues, Souhir Neffati, Laurence Raizonville, Mounia Ezzalfani, Fatima Laki, Anne Vincent Salomon, Jean-Yves Pierga, Véronique Mosseri
Publikováno v:
Journal of Clinical Oncology. 38:571-571
571 Background: Preclinical studies have shown that cell lines and murine models of TNBC phenotype are more sensitive to PARP1 inhibitors. This evidence provides strong rationale for developing a new therapeutic approach to TNBC based on targeting th
Autor:
Roman Rouzier, Delphine Hequet, Fabien Reyal, Alexandra Arfi, Sandrine Baffert, Cyrille Huchon, Souhir Neffati, Bernard Asselain, Anne-Laure Soilly
Publikováno v:
BMJ Open
IntroductionReturn to work (RTW) after breast cancer (BC) is still a new field of research. The factors determining shorter sick leave duration of patients with BC have not been clearly identified. The aim of this study was to describe work during BC
Autor:
Lobna Bouacida, Ali Bouslama, Meriem Romdhane, Jihène Rejeb, Asma Omezzine, Imen Boumaiza, Nabila Ben Rejeb, Lamia Rebhi, Ahmed Ben Abdelaziz, Souhir Neffati
Publikováno v:
Advances in Epidemiology. 2014:1-10
Objectives. Metabolic syndrome (MetS) is a major risk factor of CVD. The aim of the present study is to determine the prevalence of the MetS, its components, and its different profiles according to NCEP-ATP III 2001, IDF 2005, and JIS 2009 definition
Autor:
Khalifa Limem, Souhir Neffati, Zouhaier Bourfifa, Mohamed Ali Smach, Bassem Charfeddine, Monia Ksouri, Imen Braham, Hedi Dridi, Aida Mtar, Jihene Ben Abdallah
Publikováno v:
Annales de biologie clinique. 69:693-697
The Maroteaux-Lamy disease, or mucopolysaccharidosis type VI is an inherited metabolic disorder severe and rare. It is caused by a deficiency of the enzyme arylsulfatase B. It is characterized by a heterogeneous clinical, radiological and genetic. We
Autor:
Véronique Diéras, L. Venat-Bouvet, E. Luporsi-Gely, Marc Espié, Séverine Guiu, F-C Bidard, Véronique D'Hondt, Marc A. Bollet, V. Servent Hanon, Coraline Dubot, J-Y Pierga, Alain Lortholary, Souhir Neffati, M.P. Sablin, H Bourgeois, William Jacot, PH Cottu, Frédérique Berger
Publikováno v:
Annals of Oncology. 28:v32